Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment
نویسندگان
چکیده
منابع مشابه
Soluble CD40 ligand in acute coronary syndromes.
BACKGROUND CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition in patients with acute coronary syndromes. METHODS Serum levels of soluble CD40 ligand were measured in 1088 patients with acute coronary syndr...
متن کاملCardiopulmonary bypass induces release of soluble CD40 ligand.
BACKGROUND Cardiopulmonary bypass (CPB) is known to induce platelet activation, thrombosis, thrombocytopenia, and a systemic inflammatory response. It is known that CD40 ligand (CD40L) exists in platelets, that a soluble form of this protein (sCD40L) is released on platelet activation, that platelets are the primary source of sCD40L in blood, and that sCD40L is involved in thrombosis and inflam...
متن کاملCharacterization of soluble CD40 ligand released from human activated platelets.
We report here that soluble CD40 ligand (sCD40L) is released from human platelets when activated with collagen or thrombin. The sCD40L was detectable in the culture supernatants of platelets within 30 min after stimulation in vitro, and reached maximal levels in 3 h. The release was blocked by the metalloproteinase inhibitor, KB8301, indicating that the soluble CD40L is made by cleaving the mem...
متن کاملSoluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization
Plasma soluble CD40 ligand (sCD40L) is mainly generated by cleavage of CD40L from the surface of activated platelets, and therefore considered a platelet activation marker. Although the predictive value of sCD40L for ischemic events has been demonstrated in patients with acute coronary syndromes (ACS), studies on the association of sCD40L with cardiovascular outcomes in lower risk populations y...
متن کاملThe soluble CD40 ligand sCD154 in systemic lupus erythematosus.
We found that the plasma of patients with active systemic lupus erythematosus (SLE) could induce a human B-cell line (Ramos) to express high levels of immune accessory molecules that are commonly found on blood B cells of patients with active SLE. The ability of SLE plasma to induce such phenotypic changes could be abrogated by neutralizing antibodies specific for the CD40 ligand (CD154) but no...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2012
ISSN: 0008-543X
DOI: 10.1002/cncr.27654